Discovery Laboratorie's (DSCO) AFECTAIR Receives FDA Clearance to be Marketed in US
Up)
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR® is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support.
"We are pleased to have AFECTAIR registered with the FDA and we are eager to move this proprietary technology to commercialization in the latter part of 2012," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "Our ability to bring AFECTAIR to market is a testament to our commitment to advancing a new standard in respiratory critical care."
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
"We are pleased to have AFECTAIR registered with the FDA and we are eager to move this proprietary technology to commercialization in the latter part of 2012," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "Our ability to bring AFECTAIR to market is a testament to our commitment to advancing a new standard in respiratory critical care."
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
